https://www.zacks.com/stock/news/2198897/moderna-mrna-soars-on-upbeat-data-from-cancer-therapy-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2198897
Dec 15, 2023 - Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
zc:-7728944820947298485
0
https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156
Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
zc:6239401725016099411
0
https://www.zacks.com/stock/news/2242089/down-14-35-in-4-weeks-here-s-why-galapagos-nv-glpg-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2242089
Mar 18, 2024 - Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zc:-4900464948980423759
0
https://www.zacks.com/stock/news/2243694/bayer-s-bayry-elinzanetant-meets-goals-in-third-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243694
Mar 20, 2024 - Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.
zc:8802658197567980243
0
https://www.zacks.com/stock/news/2249839/bristol-myers-bmy-wins-ec-nod-for-reblozyl-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249839
Apr 03, 2024 - Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
zc:1401251990396007315
0
https://www.zacks.com/stock/news/2249692/after-plunging-7-94-in-4-weeks-here-s-why-the-trend-might-reverse-for-galapagos-glpg?cid=CS-ZC-FT-tale_of_the_tape|rsi-2249692
Apr 03, 2024 - The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zc:5981501426938149623
0
https://www.zacks.com/stock/news/2251537/fate-therapeutics-fate-surges-86-4-ytd-on-pipeline-progress?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251537
Apr 05, 2024 - Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
zc:8612020494465543061
0
https://www.zacks.com/commentary/2195934/new-strong-buy-stocks-for-december-13th?cid=CS-ZC-FT-zacks_1_rank_additions-2195934
Dec 13, 2023 - TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.
zc:-8476180361115797828
0
https://www.zacks.com/commentary/2197102/best-momentum-stocks-to-buy-for-december-13th?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2197102
Dec 13, 2023 - GLPG, BBVA and TW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 13, 2023.
zc:-3136543129014420408
0
https://www.zacks.com/stock/news/2200047/merck-mrk-gets-eu-nod-for-expanded-use-in-gastric-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200047
Dec 19, 2023 - Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
zc:-6486385984638128375
0